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Summary The roles of exogenous sex hormones and reproductive factors in the causation of malignant
melanoma of the skin in women were examined in a case-control study of 276 patients and 276 matched
controls in Western Australia. There was no consistent evidence of a relationship between the incidence rates
of different histogenetic types of melanoma and age at menarche, duration of menstrual life, degree of
obesity, number of pregnancies more than 20 weeks in duration or use of oral contraceptive preparations
(OCP). Exposure to OCP was examined separately for different age periods and in different intervals of time
before diagnosis; no consistent trend emerged. There was borderline evidence of an association of superficial
spreading melanoma with duration of use of unopposed oestrogens. On the basis of seven studies of the
relationship of melanoma to OCP published to date, we estimate that the total incidence rate of melanoma in
OCP ever-users is unlikely to be increased by more than one third the rate in never-users.
There is a physiological basis for the hypothesis
that the frequency of malignant melanoma in
women is influenced by hormonal or reproductive
factors. Oestrogens alone, and combinations of
oestrogens and progesterone, stimulate melanocyte
division and melanogenic activity. These effects
have been observed in animal experiments (Snell &
Bischitz, 1960) and are presumably the underlying
cause of hyperpigmentation in women taking oral
contraceptives (Jelinek, 1970). Increased cell
division and cellular activity are recognised as
general properties of cancer promoters (Greenbaum
& Weinstein, 1975). Oestrogen receptors have been
found in cells from 12% to 46% of human
melanomas (Fisher et al., 1976; Creagan et al.,
1980).
Sadoff et al. (1973) and Lee & Storer (1980) have
proposed that a hormonal factor, possibly related
to childbearing, may increase the risk of melanoma
in premenopausal women. Their view is supported
by peaks in the ratios of female to male rates of
melanomas of the skin and eye in the later years of
reproductive life (Lee & Storer, 1981; 1982), and by
anecdotal evidence that pregnancy may promote
melanoma growth (Allen, 1955; Stewart, 1955).
Despite these descriptive observations, in which
some discrepancies have been noted (Holman &
Armstrong, 1981), the relationship of melanoma to
reproductive factors such as number of pregnancies
has been quantified only recently (Holly et al.,
1983).
At least six studies have examined the
relationship of melanoma to oral contraceptives
(OCP) and other oestrogenic preparations (Beral et
al., 1977; Ramcharan et al., 1981; Adam et al.,
Correspondence: B.K. Armstrong.
Received 15 March 1984, accepted 6 August 1984.
E
1981; Kay, 1981; Bain et al., 1982; Helmrich et al.,
1983 unpublished; Holly et al., 1983). In one of the
two positive studies a specific association was
observed between OCP use and superficial
spreading melanoma, but apparently not with other
histogenetic subtypes (Holly et al., 1983).
In this report we present results from a case-
control study of cutaneous malignant melanoma in
Western Australia. Our aim is to evaluate further
the putative role of female sex hormones, both
endogenous and exogenous, in the aetiology of
different melanoma subtypes.
Materials and methods
The sources of study subjects and methods of data
collection and analysis have been described in detail
in previous reports from the West Australian Lions
Melanoma Research Project (Holman 1983;
Holman & Armstrong, 1983, 1984). In this report,
the analysis has been confined to women.
In brief, the cases were 278 female patients with
histologically proven preinvasive or invasive
melanoma. They formed 75% of a total of 373
eligible female cases aged <80 years, who were
incident in accessible regions of Western Australia
from January 1st 1980 to November 5th 1981. The
reasons for failure to interview eligible patients
were permission witheld by the attending physician
(48 cases), patient's refusal to participate (31 cases),
migration (10 cases), mental disability (5 cases) and
death (1 case). Sections of the tumours of all except
7 of the 278 selected cases were reviewed by a panel
of 6 pathologists who assigned them to either the
Hutchinson's melanotic freckle (HMF), superficial
spreading (SSM), unclassifiable (UCM) or nodular
(NM) histogenetic types according to the
© The Macmillan Press Ltd., 1984674 C.D.J. HOLMAN et al.
classification of McGovern et al. (1973). The most
common histogenetic type in women was SSM
(62% of reviewed cases). Patients ranged in age
from 10 to 79 years at diagnosis, and had a mean
age of 44.9 years.
For each case, a female control subject matched
on 5-year birth period and electoral subdivision was
randomly selected from the Australian
Commonwealth Electoral Roll. For 7 cases aged
<18 years, female controls of the same age were
randomly selected from the student roll of a public
school. In all 458 potential controls were selected,
of whom 12% were untraceable and 27% refused
to participate.
The methods used to contact potential
participants and to solicit their cooperation were
identical for cases and controls. Subjects were
initially contacted by mail and were visited either
at home (97%) or in the workplace by a trained
nurse interviewer who administered a highly
structured questionnaire entitled "Environment,
Lifestyle and Health". The purpose of the interview
was not otherwise stated, and as far as possible the
interviewers were not informed of which subjects
were cases and which were controls.
A wide range of possible causal factors, including
constitutional and hereditary factors, sun exposure,
diet and exposures to known or suspected
carcinogens were explored during the interview. Of
relevance to this report were menstrual and
obstetric histories, weight and height measured by
the interviewer, and history of use of OCP or other
oestrogenic preparations.
All except one case and her matching control
were postpubertal, and were asked the age at which
their first menstrual period had occurred and if
they still had periods. Women whose periods had
ceased for at least one year, and who were not
pregnant or breast feeding, were asked their age at
their last menstrual period, and whether menopause
had occurred naturally or as the result of a surgical
procedure. Subjects were asked if they had ever
been pregnant, and if so, their number of
pregnancies of 20 or more weeks in duration, their
age at first pregnancy and the interval since their
last pregnancy. Using the measurements obtained
by interviewers, Quetelet's index was calculated as
weight/height2.
For women who had ever used OCPs or other
oestrogenic preparations, a separate record of each
interval of use was made, including the first and
last years and duration of use to the nearest month.
To assist recall, subjects were shown a list of trade
names of OCP available in Western Australia, and
a list of trade names of other preparations
containing oestrogens.
The methods of analysis followed those described
by Breslow & Day (1981) for matched case-control
studies. Odds ratios were calculated by conditional
maximum likelihood estimation. Two control
subjects who gave a history of excision of a
malignant mole were excluded from analysis
together with their matching cases.
Results
Menstrual history
The estimated effects of age at menarche on the
incidence rates of all melanomas combined and of
each histogenetic type are shown in Table I. There
was no evidence of any trend in the odds ratios
that would suggest an association. The relationship
of all melanomas to duration of menstrual life was
examined in 49 case-control pairs concordant for
having experienced natural menopause. The trend
in these results was inconsistent. Compared with
postmenopausal women whose duration of
menstrual life had been 35 years or less, odds ratios
for melanoma were 2.18 (95% CI 0.80-5.90) in
women with a 36-38 year menstrual history, and
0.82 (0.35-1.90) in those who had menstruated for
39 or more years.
Pregnancy
In relation to ever being pregnant (82% of subjects)
the odds ratio for all melanomas was 0.97 (0.55-
1.67, P=0.895), and for SSM it was 0.84 (0.41-
1.71, P=0.735). There was little evidence that the
number of pregnancies of at least 20 weeks in
duration affected the rate of any histogenetic type
of melanoma (Table II). Results pertaining to age
at first pregnancy and interval since last pregnancy
were similarly not suggestive of an effect. In
comparison with nulliparous women, odds ratios
for all melanomas were 0.99 (0.56-1.74) in women
whose first pregnancy occurred at age 25 years or
older, 0.87 (0.47-1.59) for ages 22-24 years and
0.99 (0.55-1.79) in women aged 21 years or less at
the time of their first pregnancy (P=0.928). For
SSM the corresponding results were 0.88 (0.42-
1.82) for ages _25 years, 0.77 (0.35-1.70) for ages
22-24 years and 0.85 (0.41-1.79) for ages <21
years (P=0.697).
Obesity
Degree of obesity assessed by Quetelet's index was
studied because of the known association of plasma
oestrogen levels with obesity, especially in
postmenopausal women (de Waard, 1982). The
relationships of melanoma subtypes to Quetelet's
index measured at the time of interview are shown
in Table III. There was no evidence of any
relationship in these results, nor in results obtained
when the analyses of all melanomas and SSM were
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Table I Relationship of histogenetic types of malignant melanoma to age
at menarche
Age at menarche
in years
> 13 13-14 15+ P-value
(188)' (251) (109) for trend
All melanomas (274)b
OR 1.00 1.09 0.89
95% CI 0.74-1.60 0.54-1.47 0.800
Histogenetic types
HMF (37)
OR 1.00 0.66 1.14
95% CI 0.23-1.89 0.33-3.94 0.927
SSM (165)
OR 1.00 1.11 0.71
95% CI 0.68-1.80 0.37-1.37 0.487
UCM (52)
OR 1.00 1.68 1.55
95% CI 0.65-4.32 0.46-5.21 0.362
NM (13)
OR 1.00 1.00 1.00
95% CI 0.14-7.13 0.03-29.95 c
aTotal number of subjects in each category.
bNumber of case-control pairs.
cNo trend.
Table II Relationship of histogenetic types of malignant melanoma to number of
pregnancies of 20 or more weeks duration
Number ofpregnancies
None 1-2 3-4 5+ P-value
(112)- (212) (172) (56) for trend
All melanomas (276)b
OR 1.00 0.92 1.11 0.73
95% CI 0.54-1.55 0.61-2.01 0.33-1.65 0.759
Histogenetic types
HMF (37)
OR 1.00 0.68 0.75 1.05
95% CI 0.10-4.49 0.12-4.66 0.08-13.52 0.821
SSM (167)
OR 1.00 0.79 1.39 0.86
95% CI 0.41-1.53 0.64-3.00 0.28-2.60 0.511
UCM (52)
OR 1.00 1.30 0.62 0.48
95% CI 0.39-4.31 0.12-3.18 0.08-2.98 0.263
NM (13)
OR 1.00 1.00 0.50c
95% CI 0.12-8.56 0.07-3.73 0.441
aTotal number of subjects in each exposure category.
bNumber of case-control pairs.
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Table III Relationship of histogenetic types of malignant
measured Quetelet's index
melanoma in women to
Quetelet's index
<19 19-24 25-30 31+ P-value
(46)a (326) (146) (34) for trend
All melanomas (276)b
OR 1.00 1.30 1.32 0.90
95% CI 0.67-2.56 0.64-2.69 0.36-2.23 0.934
Histogenetic types
HMF (37)
OR 1.00 1.68 1.33 1.33
95% CI 0.26-10.91 0.19-9.57 0.14-12.65 0.941
SSM (167)
OR 1.00 1.73 1.73 0.93
95% CI 0.68-4.37 0.66-4.56 0.25-3.40 0.860
UCM (52)
OR 1.00 0.77 0.89 0.89
95% CI 0.20-2.99 0.20-3.91 0.12-6.48 0.981
NM (13)
OR 1.00 0.95 1.31C
95% CI 0.05-17.01 0.07-23.68 0.741
aTotal number of subjects in each category.
bNumber of case-control pairs.
C2530 and 31 + combined.
Oral contraceptive preparations
Past or present use of OCPs was reported by 53%
of subjects. For ever-use of OCPs an odds ratio of
0.97 (0.59-1.61, P=0.903) was observed for all
melanomas, whereas for SSM the odds ratio was
1.11 (0.56-2.19, P=0.871). Odds ratios pertaining
to total duration of OCP use (i.e., the sum of
durations of each interval of use) are given in Table
IV. While the results are not inconsistent with an
elevation of the rates of HMF and SSM in women
who had used OCP for 2 or more years, the
estimated effects were readily explained by chance
and there was only weak evidence of a dose-
response relationship (P=0.251 for all melanomas
and P=0.177 for SSM).
Because of the possibility of confounding, the
relationship of SSM to duration of OCP use was
re-examined controlling for SSM risk factors
identified elsewhere in the study. These were skin
reaction to sunlight, hair colour, number of raised
naevi on the arms, age at arrival of migrants to
Australia, level of residential sun exposure and
degree of weekend recreational sun exposure at ages
10-24 and frequencies of outdoor activities in
summer (Holman, 1983; Holman & Armstrong,
1984). The odds ratios observed following inclusion
of these factors in the conditional logistic regression
model were 0.78 (0.32-1.94) in women using OCP
for less than 2 years, 2.24 (0.73-6.81) for 2-4 years
of use, and 1.62 (0.53-4.93) in women with a
history of 5 or more years of OCP use.
The associations of all melanomas and melanoma
subtypes with OCP use were also examined within
intervals of 10 or more years, 5-9 years and less
than 5 years before diagnosis of the case (Table V).
The odds ratios in Table V compare OCP ever-
users with never-users ascertained solely on the
basis of exposure information derived from each
time period. Except for HMF, which had odds
ratios associated with very wide confidence
intervals, there was little empirical evidence of an
effect of OCP use in any of the time periods under
study. A similar analysis was performed on
exposure to OCP within each of the age intervals
10-19 years, 20-29 years and 30 or more years,
again without consistent evidence of any effect.
Other oestrogenic preparations
Fourteen per cent of subjects had ever taken
hormone tablets or injections containing an
oestrogen but no progestagen. Reasons for
prescription of the preparations included alleviation
of symptoms of menopause (59%), regulation of
menstrual bleeding (19%) and indications related to
pregnancy and lactation (19%). In ever-users of
unopposed oestrogens the odds ratios were 1.52
(0.87-2.66, P=0.149) for all melanomas and 1.91
(0.88-4.22, P=0.112) for SSM.
Table VI shows the associations of histogenetic
types of melanoma with total duration of oestrogen
use. For SSM there was borderline evidence of a
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Table IV Relationship of histogenetic types of malignant melanoma to duration of
use of the oral contraceptive pill (OCP)
Duration ofOCP in years
Nevera <2 2-4 5+ P-value
(260) (87) (93) (112) for trend
All melanomas (276)b
OR 1.00 0.66 1.21 1.13
95% CI 0.37-1.19 0.65-2.23 0.62-2.04 0.251
Histogenetic types
HMF (37)
OR 1.00 0.28 4.65c
95% CI 0.03-2.60 0.54-40.40 0.145
SSM (167)
OR 1.00 0.81 1.69 1.47
95% CI 0.39-1.67 0.73-3.93 0.67-3.20 0.177
UCM (52)
OR 1.00 0.55 0.68 0.75
95% CI 0.14-2.25 0.20-2.28 0.20-2.81 0.802
NM (13)
OR 1.00 0.33d
95% CI 0.02-3.56 0.617
aTotal number of subjects in each exposure category.
bNumber of case-control pairs.
C2-4 y and 5+ y combined.
dEver-use of OCP.
Table V Relationship of histogenetic types of malignant melanoma
to ever-use of OCP in different time intervals
lime interval in years
10+ 5-9 0-4
prediagnosis prediagnosis prediagnosis
(196)' (174) (144)
All melanomas (276)b
OR 1.06 1.06 1.00
95% CI 0.65-1.73 0.65-1.70 0.60-1.66
Histogenetic types
HMF (37)
OR 2.50 1.00 2.00
95% CI 0.43-18.56 0.21-4.73 0.14-55.65
SSM (167)
OR 1.25 1.19 0.92
95% CI 0.67-2.34 0.64-2.21 0.50-1.68
UCM (52)
OR 0.67 0.75 1.00
95% CI 0.21-2.04 0.23-2.37 0.25-3.96
NM (13)
OR c 1.50 1.50
95% 0.21-12.78 0.21-12.78
'Total number of over-users in time interval
bNumber of case-control pairs.
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Table VI Relationship of histogenetic types of malignant melanoma in
women to duration of use of unopposed oestrogens
Duration ofoestrogen use
in months
Never 1-12 13+ P-value
(476)a (36) (40) for trend
All melanomas (276)b
OR 1.00 1.56 1.49
95% CI 0.76-3.19 0.76-2.92 0.184
Histogenetic types
HMF (37)
OR 1.00 1.67c
95% CI 0.35-8.77 0.724
SSM (167)
OR 1.00 1.68 2.26
95% CI 0.70-4.07 0.82-6.21 0.082
UCM (52)
OR 1.00 5.00 0.67
95% CI 0.58-42.80 0.11-3.99 0.889
NM (13)
OR 1.00 0.67c
95% CI 0.08-4.87 0.655
aTotal number of subjects in each exposure category.
bNumber of case-control pairs.
cEver-use of unopposed oestrogens.
rate of SSM in users of 13 or more months
duration being estimated at over twice the rate in
never-users (OR=2.26). Little evidence of a
relationship to any other histogenetic type was
observed.
The analysis of SSM with duration of oestrogen
use was also repeated controlling for SSM risk
factors previously identified. This analysis produced
no overall loss in the strength of association of
SSM with oestrogen use, but did produce
inconsistency in the trend in odds ratios. The
adjusted odds ratios were 2.51 (0.71-8.87) in
women who used oestrogens for 12 months or less,
and 2.15 (0.52-8.55) for use of greater than 12
months.
Discussion
It is widely known that Australia has a high
incidence rate of malignant melanoma, generally
thought to result from high levels of sunlight
exposure. In the presence of other exposures such
as sunlight, incidence rate ratios for hormonal
factors could be altered substantially, depending on
the nature of any effect modification that might
occur. It may be unwise, therefore, to assume that
our results may be generalised to low incidence
populations as readily as they might be to other
high incidence populations.
With this proviso, the results of this study give
no support for a role of endogenous sex hormones
or related phenomena in the aetiology of melanoma
in women. None of the histogenetic subtypes
appeared to occur at an increased rate in
association with early age at menarche, long
duration of menstrual life or obesity. similarly,
Holly et al. (1983) found no relationship of either
SSM or all melanomas as a group with age at
menopause or body weight of women at age 30
years. In contrast cancers of the breast and
endometrium, both thought to be promoted by
oestrogens, show associations with early menarche,
late menopause and obesity (Petrakis et al., 1982;
de Waard, 1982).
Contrary to past suspicions that oestrogens, and
perhaps pregnancy as a consequence, may be a
promotional factor, we, like Holly et al. (1983),
observed no association of melanoma with number
of pregnancies. Holly et al. (1983) did report a 3-
fold increase in the rate of SSM in women who
delayed childbearing until age 31 years or older
compared with those aged 20 years or less at the
birth of their first child. In this study only 4% of
subjects first bore a child at over 30 years of age.
Thus, our results cannot necessarily argue against
an effect of very late childbearing, although we find
this hypothesis difficult to reconcile with the
apparent lack of an increased risk in nulliparous
women.SEX HORMONES AND REPRODUCTIVE FACTORS IN MELANOMA
Table VII Estimated incidence rate ratios from seven studies of the
relationship of malignant melanoma in women to ever-use of the oral
contraceptive pill
Estimated
incidence
Study Type rate ratio 95% CI
Ramcharan et al., 1981' Cohort 3.5 1.4-9.0
Adam et al., 1981 Case-control 1.34" 0.92-1.96
1.13c 0.73-1.75
Kay, 1981 Cohort 1.46 0.73-2.91
Bain et al., 1982 Case-control 0.93 0.64-1.36
Helmrich et al., 1983 Case-control 0.9 0.6-1.3
Holly et al., 1983 Case-control 1.16 0.70-1.91
Holman et al, 1984 Case-control 0.97 0.59-1.61
Combined estimate 1.12 0.94-1.33
aFirst reported by Beral et al. (1977).
bBased on clinical records, used in calculation of the combined estimate.
cBased on a postal questionnaire.
The putative associations of melanoma with use
of OCP and other oestrogenic preparations are
more problematic. We have summarised in Table
VII the results of studies published to date,
including the present, which have compared the
incidence rates of all melanomas in OCP ever-users
and non-users. Strong evidence of a relationship of
melanomas as a group to OCP use was obtained
only in the Walnut Creek Contraceptive Drug
Study (Beral et al., 1977; Ramcharan et al., 1981).
One other cohort study and 5 case-control studies
have produced essentially negative results. Also
given in Table VII is an estimate of the melanoma
incidence rate ratio in OCP ever-users compared
with never-users, based on the evidence from all 7
studies. This was calculated as a weighted average
of estimates from each study, with weights inversely
proportional to the variances. The combined
estimate was 1.12 with a 95% confidence interval of
0.94-1.33. It appears, therefore, that any use of
OCPs, if it is a risk factor at all, is unlikely to
increase the incidence rate of melanoma by more
than one third the rate in women never exposed to
OCPs. It must be recognised that this conclusion
does not necessarily apply to populations of very
long term users, or for time periods long after first
use. There has been limited experience to date of
exposure in these categories and there was some
evidence in our data, albeit very weak, of increasing
incidence of melanoma in long term users and after
a long latent interval.
With respect to particular histogenetic types of
melanoma, Holly et al. (1983) observed a dose-
response relationship of SSM with duration of OCP
use, but not with duration of oestrogen use at the
time of menopause. Their analysis controlled
potential confounding by educational status, but
not differences in sun exposure habits. We found
little evidence of association of SSM with OCP.
Nevertheless, our results should not be interpreted
as completely inconsistent with those of Holly et al.
(1983), since the upper bounds of our confidence
intervals for the crude odds ratios in long term
OCP users were around 3-4 and the upper bounds
for odds ratios with possible confounding variables
controlled were near 5-7.
The borderline finding of association of SSM
with unopposed oestrogen use in this study
appeared to be largely unexplained by any
confounding effect. This result warrants further
investigation. However, in view of the lack of
association of SSM with indicators of endogenous
oestrogen exposure, and the negative results of
Holly et al. (1983), chance is perhaps the most
likely explanation.
In any future study of the role of OCPs or other
oestrogens in melanoma causation it will be
important to perform separate analyses on the
histogenetic subtypes of melanoma. An investigator
reporting a positive result should also be able to
demonstrate that the association is not due to
confounding by factors related to sunlight exposure
habits which, at least in an extension of the Walnut
Creek Contraceptive Drug Study (Ramcharan et
al., 1981), appeared to differ between OCP users
and non-users.
The study was funded by the Lions Clubs of Western
Australia and the Canccr Foundation of Western
Australia. C.D.J.H. was supported by a Medical
Postgraduate Research Scholarship of the National Health
and Medical Research Council of Australia and a
Research Training Fellowship of the International Agency
for Research on Cancer.
The authors are grateful to members of the melanoma
pathology panel and to Mrs Janice Watt and Mrs Susan
Holland for their dedication as interviewers. The
questionnaire was based on that used in a similar study in
Canada by Dr J.M. Elwood.
679680 C.D.J. HOLMAN et al.
References
ADAM, S.A., SHEAVES, J.K., WRIGHT, N.H., MOSSER, G.,
HARRIS, R.W. & VESSEY, M.P. (1981). A case-control
study of the possible association between oral
contraceptives and malignant melanoma. Br. J.
Cancer, 44, 45.
ALLEN, E.P. (1955). Malignant melanoma. Spontaneous
regression after pregnancy. Br. Med. J., ii, 1067.
BAIN, C., HENNEKENS, C.H., SPEIZER, F.E., ROSNER, B.,
WILLET, W. & BELANGER, C. (1982). Oral
contraceptive use and malignant melanoma. J. Nat
Cancer Inst., 68, 537.
BERAL, V., RAMCHARAN, S. & FARIS, R. (1977).
Malignant melanoma and oral contraceptive use
among women in California. Br. J. Cancer, 36, 804.
BRESLOW, N.E. & DAY, N.E. (1980). Statistical Methods in
Cancer Research, Vol. 1. The Analysis of Case-control
studies. Int. Agency Res. Cancer: Lyon.
CREAGAN, E.T., INGLE, J.N., WOODS, J.E., PRITCHARD,
D.J. & JIANG, N.-S. (1980). Estrogen receptors in
patients with malignant melanoma. Cancer, 46, 1785.
DEWAARD, F. (1982). Cancer by Tissue of Origin: Uterine
Corpus. In Cancer Epidemiology and Prevention, p.
901. (Ed. Schottenfeld & Fraumeni) W.B. Saunders
Co.: Philadelphia.
FISHER, R.I., NEIFELD, J.P. & LIPPMAN, M.E. (1976).
Oestrogen receptors in human malignant melanoma.
Lancet, ii, 337.
GREENBAUM, E. & WEINSTEIN, I.B. (1975). Relevance of
the concept of tumor promotion to the causation of
human cancer. In Cancer. A Comprehensive Treatise
Vol. 1, p. 27. (Ed. Becker) Plenum Press: New York.
HELMRICH, S.P., ROSENBERG, L., SHAPIRO, S.,
KAUFMAN, D.W., MILLER, D.R. & MIETTINEN, O.S.
(1983). Malignant melanoma and oral contraceptive
use. SER '83, 16th Annual Meeting of The Society for
Epidemiologic Research, A56. University of Manitoba:
Winnepeg.
HOLLY, E.A., WEISS, N.S. & LIFF, J.M. (1983). Cutaneous
melanoma in relation to exogenous hormones and
reproductive factors. J. Natl Cancer Inst., 70, 827.
HOLMAN, C.D.J. (1983). Risk Factors in the Causation of
Human Malignant Melanoma of the Skin. Doctoral
thesis, University of Western Australia, 1982.
University Microfilms International: Ann Arbor,
Michigan.
HOLMAN, C.D.J. & ARMSTRONG, B.K. (1981). Malignant
melanoma in British women. Lancet, i, 1100.
HOLMAN, C.D.J. & ARMSTRONG, B.K. (1983).
Hutchinson's melanotic freckle melanoma associated
with non-permanent hair dyes. Br. J. Cancer, 48, 599.
HOLMAN, C.D.J. & ARMSTRONG, B.K. (1984). Pigmentary
traits, ethnic origin, benign naevi and family history as
risk factors for cutaneous malignant melanoma. J.
Natl Cancer Inst., 72, 257.
JELINEK, J.E. (1970). Cutaneous side effects of oral
contraceptives. Arch. Derm., 101, 181.
KAY, C.R. (1981). Malignant melanoma and oral
contraceptives. Br. J. Cancer, 44, 479.
LEE, J.A.H. & STORER, B.E. (1980). Excess of malignant
melanoma in women in the British Isles. Lancet, ii,
1337.
LEE, J.A.H. & STORER, B.E. (1981). Malignant melanoma
female/male death ratios. Lancet, i, 1419.
LEE, J.A.H. & STORER, B.E. (1982). Further studies on
skin melanomas apparently dependent on female sex
hormones. Int. J. Epidemiol., 11, 127.
McGOVERN, V.J., MIHM, M.C. Jr., BAILLY, C. & 9 others.
(1973). The classification of malignant melanoma and
its histologic reporting. Cancer, 32, 1446.
PETRAKIS, N.L., ERNSTER, V.L. & KING, M.C. (1982).
Cancer by Tissue of Origin: Breast. In Cancer
Epidemiology and Prevention, p. 855. (Ed. Schottenfeld
& Fraumeni) W.B. Saunders Co.: Philadelphia.
RAMCHARAN, S., PELLEGRIN, F.A., RAY, R. & HSU, J.-P.
(1981). The Walnut Creek Contraceptive Drug Study,
Vol. III. An interim Report., p. 53. NIH Publ. 81-564.
U.S. Government Printing Office: Washington D.C.
SADOFF, L., WINKLEY, J. & TYSON, S. (1973). Is malignant
melanoma an endocrine dependent tumour? The
possible adverse effect of estrogen. Oncology, 27, 246.
SNELL, R.S. & BISCHITZ, P.G. (1960). The effect of large
doses of estrogen and estrogen and progesterone on
melanin pigmentation. J. Invest. Derm., 35, 73.
STEWART, H. (1955). A case of malignant melanoma and
pregnancy. Br. Med. J., i, 647.